Curia, formerly AMRI, a contract research, development and manufacturing organization (CRDMO), has appointed Niall Condon as president of its Manufacturing Division, effective immediately.
 
Condon will drive growth and be responsible for operational delivery of Curia’s commercial manufacturing services and products, including API and Drug Product. He will also serve as a member of Curia’s executive committee. Condon succeeds Curia’s retiring president of Manufacturing, Steve Lichter.
 
“I’m very pleased to welcome Niall to Curia at this critical point in our growth journey,” said Curia chairman and CEO John Ratliff. “Steve has transformed our manufacturing capabilities over the past few years with a blend of scientific depth and operational excellence. I am confident that Niall will continue to drive our progress with his extensive experience and an exceptional record of success leading global teams across all aspects of the global biopharmaceutical supply chain.”
 
Condon most recently served as head of API and OSD Manufacturing at Viatris, which was formed through the merger of Mylan and Upjohn Pfizer. Previously, he was a senior vice president at Pfizer, where he built a standalone global supply organization, the Upjohn Division. Condon spent more than 30 years at Pfizer in roles of increasing responsibility in manufacturing and operations, based at locations in the U.S., Europe and Asia.
 
He earned his Bachelor of Science in Chemical Engineering at Munster Technological University, Ireland, and his Master of Business Administration at Rensselaer Polytechnic Institute, New York.
 
“I’m excited to be joining Curia with its mission of life-changing life science,” said Condon. “The CDMO industry is dynamic and Curia is uniquely positioned to serve customers with its innovative portfolio of solutions and products spanning R&D through manufacturing. I’m looking forward to meeting its talented community of colleagues and making an impact for our customers and the patients they serve.”